25,999 Shares in Sabra Healthcare REIT, Inc. $SBRA Bought by Allstate Corp

Allstate Corp purchased a new stake in Sabra Healthcare REIT, Inc. (NASDAQ:SBRA) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 25,999 shares of the real estate investment trust’s stock, valued at approximately $492,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of SBRA. Principal Financial Group Inc. raised its holdings in shares of Sabra Healthcare REIT by 21.6% in the fourth quarter. Principal Financial Group Inc. now owns 24,953,351 shares of the real estate investment trust’s stock valued at $472,617,000 after buying an additional 4,431,897 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. raised its holdings in shares of Sabra Healthcare REIT by 1,019.8% in the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 3,005,374 shares of the real estate investment trust’s stock valued at $56,922,000 after buying an additional 2,736,993 shares during the last quarter. Balyasny Asset Management L.P. purchased a new stake in shares of Sabra Healthcare REIT in the second quarter valued at about $49,955,000. Qube Research & Technologies Ltd raised its holdings in shares of Sabra Healthcare REIT by 856.5% in the second quarter. Qube Research & Technologies Ltd now owns 1,398,965 shares of the real estate investment trust’s stock valued at $25,797,000 after buying an additional 1,252,708 shares during the last quarter. Finally, JPMorgan Chase & Co. raised its holdings in shares of Sabra Healthcare REIT by 33.7% in the third quarter. JPMorgan Chase & Co. now owns 3,589,253 shares of the real estate investment trust’s stock valued at $66,904,000 after buying an additional 903,841 shares during the last quarter. 99.40% of the stock is owned by hedge funds and other institutional investors.

Sabra Healthcare REIT Trading Down 1.9%

Shares of SBRA opened at $19.89 on Friday. The company has a current ratio of 4.72, a quick ratio of 4.72 and a debt-to-equity ratio of 0.96. The firm’s 50-day moving average is $20.29 and its two-hundred day moving average is $19.70. Sabra Healthcare REIT, Inc. has a twelve month low of $17.13 and a twelve month high of $21.28. The firm has a market capitalization of $5.02 billion, a P/E ratio of 31.57, a PEG ratio of 1.49 and a beta of 0.67.

Sabra Healthcare REIT (NASDAQ:SBRA) last issued its earnings results on Wednesday, April 29th. The real estate investment trust reported $0.16 earnings per share for the quarter, hitting the consensus estimate of $0.16. Sabra Healthcare REIT had a net margin of 19.22% and a return on equity of 5.60%. The company had revenue of $211.74 million for the quarter, compared to analyst estimates of $209.20 million. During the same period in the prior year, the business posted $0.37 earnings per share. The firm’s revenue for the quarter was up 20.9% compared to the same quarter last year. Sabra Healthcare REIT has set its FY 2026 guidance at 1.550-1.590 EPS. On average, research analysts predict that Sabra Healthcare REIT, Inc. will post 1.51 earnings per share for the current fiscal year.

Sabra Healthcare REIT Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, May 29th. Shareholders of record on Friday, May 15th were given a dividend of $0.30 per share. This represents a $1.20 annualized dividend and a yield of 6.0%. The ex-dividend date was Friday, May 15th. Sabra Healthcare REIT’s dividend payout ratio is presently 190.48%.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on SBRA shares. Scotiabank upped their target price on shares of Sabra Healthcare REIT from $21.00 to $22.00 and gave the company a “sector perform” rating in a report on Thursday, May 21st. Weiss Ratings lowered shares of Sabra Healthcare REIT from a “buy (a-)” rating to a “buy (b+)” rating in a research note on Friday, May 1st. UBS Group boosted their price target on shares of Sabra Healthcare REIT from $21.00 to $22.00 and gave the stock a “neutral” rating in a research note on Wednesday, May 13th. Cantor Fitzgerald boosted their price target on shares of Sabra Healthcare REIT from $21.00 to $22.00 and gave the stock a “neutral” rating in a research note on Monday, May 11th. Finally, Wells Fargo & Company boosted their price target on shares of Sabra Healthcare REIT from $21.00 to $22.00 and gave the stock an “overweight” rating in a research note on Thursday, March 26th. Five equities research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $22.30.

Sabra Healthcare REIT Profile

Sabra Healthcare REIT, Inc (NASDAQ: SBRA) is a real estate investment trust that acquires, owns and operates net‐lease healthcare properties. Its diversified portfolio spans senior housing communities, skilled nursing and rehabilitation centers, outpatient medical facilities, medical office buildings, hospitals and life science properties. Sabra structures long‐term, triple‐net lease agreements with healthcare operators, providing stable rental income streams while allowing tenants to focus on patient care and operational excellence.

Serving a broad spectrum of care segments, Sabra’s tenants include both regional and national providers of assisted living, independent living, memory care, post‐acute rehabilitation and research and development laboratories.